Despite being off-patent for many years, Humalog and other insulin brands continue to make high sales, with Lilly booking around $3 billion from its product last year, $1.8 billion of which was ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

(KKTV) - A shortage of Eli Lilly insulin products continues to put Southern Colorado residents in a bind. The company announced last month that their 10-milliliter vials of Humalog and Insulin ...